Migraine Drugs Market

Migraine Drugs Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

215

Base Year:

2023

Dec - 2024

Format:

Report Code:

VMR-3915

Segments Covered

By Treatment Acute, Preventive
By Therapeutic class CGRP Monoclonal Antibodies, CGRP Small Molecule Antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs
By Route of Administration Oral, Injectable, Others
By Age group Pediatric, Adult, Geriatric
By Availability prescription drugs, Over-the-Counter (OTC) drugs
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4199 USD

Multi User License

$ 6499 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2023
Forecast Years:	2024 - 2032
Historical Years:	2018 - 2022
Revenue 2023:	USD 6.37 Billion
Revenue 2032:	USD 21.59 Billion
Revenue CAGR (2024 - 2032):	11.75%
Fastest Growing Region (2024 - 2032)	Asia Pacfic
Largest Region (2023):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global Migraine Drugs Market - Segment Analysis
1. Overview
2. Global Migraine Drugs Market, 2016 - 2028 (USD Million)
3. Global Migraine Drugs Market - by Treatment
  1. By Acute
  2. By Preventive
4. Global Migraine Drugs Market - by Therapeutic class
  1. By CGRP Monoclonal Antibodies
  2. By CGRP Small Molecule Antagonists
  3. By Acetylcholine inhibitors/ neurotoxins
  4. By Triptans
  5. By Ditans
  6. By Ergot alkaloids
  7. By NSAIDs
5. Global Migraine Drugs Market - by Route of Administration
  1. By Oral
  2. By Injectable
  3. By Others
6. Global Migraine Drugs Market - by Age group
  1. By Pediatric
  2. By Adult
  3. By Geriatric
7. Global Migraine Drugs Market - by Availability
  1. By prescription drugs
  2. By Over-the-Counter (OTC) drugs
8. Global Migraine Drugs Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
9. Market comparative analysis
North America Migraine Drugs Market - Segment Analysis
1. Overview
2. North America Migraine Drugs Market, 2016 - 2028 (USD Million)
3. North America Migraine Drugs Market, by Treatment
  1. By Acute
  2. By Preventive
4. North America Migraine Drugs Market, by Therapeutic class
  1. By CGRP Monoclonal Antibodies
  2. By CGRP Small Molecule Antagonists
  3. By Acetylcholine inhibitors/ neurotoxins
  4. By Triptans
  5. By Ditans
  6. By Ergot alkaloids
  7. By NSAIDs
5. North America Migraine Drugs Market, by Route of Administration
  1. By Oral
  2. By Injectable
  3. By Others
6. North America Migraine Drugs Market, by Age group
  1. By Pediatric
  2. By Adult
  3. By Geriatric
7. North America Migraine Drugs Market, by Availability
  1. By prescription drugs
  2. By Over-the-Counter (OTC) drugs
8. North America Migraine Drugs Market, by Country
  1. U.S.
    1. U.S. Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. U.S. Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. U.S. Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. U.S. Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. U.S. Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  2. Canada
    1. Canada Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Canada Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Canada Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Canada Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Canada Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  3. Mexico
    1. Mexico Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Mexico Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Mexico Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Mexico Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Mexico Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
Europe Migraine Drugs Market - Segment Analysis
1. Overview
2. Europe Migraine Drugs Market, 2016 - 2028 (USD Million)
3. Europe Migraine Drugs Market, by Treatment
  1. By Acute
  2. By Preventive
4. Europe Migraine Drugs Market, by Therapeutic class
  1. By CGRP Monoclonal Antibodies
  2. By CGRP Small Molecule Antagonists
  3. By Acetylcholine inhibitors/ neurotoxins
  4. By Triptans
  5. By Ditans
  6. By Ergot alkaloids
  7. By NSAIDs
5. Europe Migraine Drugs Market, by Route of Administration
  1. By Oral
  2. By Injectable
  3. By Others
6. Europe Migraine Drugs Market, by Age group
  1. By Pediatric
  2. By Adult
  3. By Geriatric
7. Europe Migraine Drugs Market, by Availability
  1. By prescription drugs
  2. By Over-the-Counter (OTC) drugs
8. Europe Migraine Drugs Market, by Country
  1. Germany
    1. Germany Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Germany Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Germany Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Germany Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Germany Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  2. UK
    1. UK Market, By Treatment
      1. By Acute
      2. By Preventive
    2. UK Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. UK Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. UK Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. UK Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  3. France
    1. France Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. France Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. France Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. France Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. France Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  4. Spain
    1. Spain Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Spain Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Spain Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Spain Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Spain Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  5. Italy
    1. Italy Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Italy Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Italy Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Italy Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Italy Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  6. BENELUX
    1. BENELUX Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. BENELUX Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. BENELUX Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. BENELUX Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. BENELUX Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  7. Rest of Europe
    1. Rest Of Europe Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Rest Of Europe Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Rest Of Europe Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Rest Of Europe Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Rest Of Europe Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
Asia Pacific Migraine Drugs Market - Segment Analysis
1. Overview
2. Asia Pacific Migraine Drugs Market, 2016 - 2028 (USD Million)
3. Asia Pacific Migraine Drugs Market, by Treatment
  1. By Acute
  2. By Preventive
4. Asia Pacific Migraine Drugs Market, by Therapeutic class
  1. By CGRP Monoclonal Antibodies
  2. By CGRP Small Molecule Antagonists
  3. By Acetylcholine inhibitors/ neurotoxins
  4. By Triptans
  5. By Ditans
  6. By Ergot alkaloids
  7. By NSAIDs
5. Asia Pacific Migraine Drugs Market, by Route of Administration
  1. By Oral
  2. By Injectable
  3. By Others
6. Asia Pacific Migraine Drugs Market, by Age group
  1. By Pediatric
  2. By Adult
  3. By Geriatric
7. Asia Pacific Migraine Drugs Market, by Availability
  1. By prescription drugs
  2. By Over-the-Counter (OTC) drugs
8. Asia Pacific Migraine Drugs Market, by Country
  1. China
    1. China Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. China Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. China Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. China Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. China Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  2. Japan
    1. Japan Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Japan Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Japan Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Japan Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Japan Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  3. India
    1. India Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. India Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. India Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. India Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. India Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  4. South Korea
    1. South Korea Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. South Korea Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. South Korea Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. South Korea Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. South Korea Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  5. South East Asia
    1. South East Asia Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. South East Asia Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. South East Asia Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. South East Asia Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. South East Asia Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Rest of Asia Pacific Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Rest of Asia Pacific Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Rest of Asia Pacific Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Rest of Asia Pacific Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
Latin America Migraine Drugs Market - Segment Analysis
1. Overview
2. Latin America Migraine Drugs Market, 2016 - 2028 (USD Million)
3. Latin America Migraine Drugs Market, by Treatment
  1. By Acute
  2. By Preventive
4. Latin America Migraine Drugs Market, by Therapeutic class
  1. By CGRP Monoclonal Antibodies
  2. By CGRP Small Molecule Antagonists
  3. By Acetylcholine inhibitors/ neurotoxins
  4. By Triptans
  5. By Ditans
  6. By Ergot alkaloids
  7. By NSAIDs
5. Latin America Migraine Drugs Market, by Route of Administration
  1. By Oral
  2. By Injectable
  3. By Others
6. Latin America Migraine Drugs Market, by Age group
  1. By Pediatric
  2. By Adult
  3. By Geriatric
7. Latin America Migraine Drugs Market, by Availability
  1. By prescription drugs
  2. By Over-the-Counter (OTC) drugs
8. Latin America Migraine Drugs Market, by Country
  1. Brazil
    1. Brazil Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Brazil Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Brazil Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Brazil Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Brazil Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  2. Argentina
    1. Argentina Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Argentina Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Argentina Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Argentina Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Argentina Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  3. Rest of Latin America
    1. Rest of Latin America Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Rest of Latin America Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Rest of Latin America Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Rest of Latin America Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Rest of Latin America Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
Middle East & Africa Migraine Drugs Market - Segment Analysis
1. Overview
2. Middle East & Africa Migraine Drugs Market, 2016 - 2028 (USD Million)
3. Middle East & Africa Migraine Drugs Market, by Treatment
  1. By Acute
  2. By Preventive
4. Middle East & Africa Migraine Drugs Market, by Therapeutic class
  1. By CGRP Monoclonal Antibodies
  2. By CGRP Small Molecule Antagonists
  3. By Acetylcholine inhibitors/ neurotoxins
  4. By Triptans
  5. By Ditans
  6. By Ergot alkaloids
  7. By NSAIDs
5. Middle East & Africa Migraine Drugs Market, by Route of Administration
  1. By Oral
  2. By Injectable
  3. By Others
6. Middle East & Africa Migraine Drugs Market, by Age group
  1. By Pediatric
  2. By Adult
  3. By Geriatric
7. Middle East & Africa Migraine Drugs Market, by Availability
  1. By prescription drugs
  2. By Over-the-Counter (OTC) drugs
8. Middle East & Africa Migraine Drugs Market, by Country
  1. GCC Countries
    1. GCC Countries Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. GCC Countries Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. GCC Countries Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. GCC Countries Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. GCC Countries Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  2. South Africa
    1. South Africa Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. South Africa Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. South Africa Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. South Africa Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. South Africa Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa Migraine Drugs Market, By Treatment
      1. By Acute
      2. By Preventive
    2. Rest of Middle East & Africa Migraine Drugs Market, By Therapeutic class
      1. By CGRP Monoclonal Antibodies
      2. By CGRP Small Molecule Antagonists
      3. By Acetylcholine inhibitors/ neurotoxins
      4. By Triptans
      5. By Ditans
      6. By Ergot alkaloids
      7. By NSAIDs
    3. Rest of Middle East & Africa Migraine Drugs Market, By Route of Administration
      1. By Oral
      2. By Injectable
      3. By Others
    4. Rest of Middle East & Africa Migraine Drugs Market, By Age group
      1. By Pediatric
      2. By Adult
      3. By Geriatric
    5. Rest of Middle East & Africa Migraine Drugs Market, By Availability
      1. By prescription drugs
      2. By Over-the-Counter (OTC) drugs
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. AbbVie Inc.
2. Amgen Inc.
3. Teva Pharmaceutical Industries Ltd.
4. GSK plc
5. Eli Lilly and Company
6. Pfizer Inc.
7. Bausch Health Companies Inc.
8. Gensco Pharma
9. Impel Pharmaceuticals Inc.
10. Tonix Medicines Inc.
11. Currax Pharmaceuticals LLC.
12. Lundbeck
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

FAQ

Frequently Asked Question

What is the global demand for Migraine Drugs in terms of revenue?

The global Migraine Drugs valued at USD 6.37 Billion in 2023 and is expected to reach USD 21.59 Billion in 2032 growing at a CAGR of 11.75%.

Which are the prominent players in the market?

The prominent players in the market are AbbVie Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., GSK plc, Eli Lilly and Company, Pfizer Inc., Bausch Health Companies Inc., Gensco Pharma, Impel Pharmaceuticals Inc., Tonix Medicines, Inc., Currax Pharmaceuticals LLC., Lundbeck.

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 11.75% between 2024 and 2032.

What are the driving factors fueling the growth of the market.

The driving factors of the Migraine Drugs include

Which region accounted for the largest share in the market?

North America was the leading regional segment of the Migraine Drugs in 2023.

Migraine Drugs Market

Migraine Drugs Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Migraine Drugs in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Quick Links

For Buying Inquiry

Migraine Drugs Market

Migraine Drugs Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for Migraine Drugs in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for Migraine Drugs Market

Vantage Point Interactive Dashboard